I also have dry eyes from time to time, and often use the single-vial Refresh drops, which I expect I will shortly re-up on as usual, despite knowing they've come under official scrutiny recently in the Senate as how their parent corporation, AbbVie (a spinoff of Abbott Labs in 2013) somehow manages to lose money in the USA while scoring profits overseas.
There are some loopholes in the 2017 Trump tax law that do enable exploitation of incentives to offshore profits Apparently AbbVie has located one of those lines of fine print, since it reported 2020 pretax loss of $4.5B onshore but a foreign pretax profit of $7.9B. Tribute to the sharp-eyed tax lawyers and accountants... and shame on members of both houses of Congress for winking at this kind of stuff constantly being slid into the arcane mess of our tax code. It really won't do any more for them all to shrug and say the bill was so huge and had so many late amendments they just couldn't manage to read it. Peasants with pitchforks will be the remedy for this studied "carelessness" one of these days, unless voters and consumers alike start holding both companies and congress critters to account.
Those eye drops work great but the plastic trash from the single-serve doses is disheartening. And the profit margin has to be huge on those things. By now any research bucks that went into them has been covered and it's all gravy with more aging eyes popping up every year thanks to the boomers providing an expanding market.